Acorda Therapeutics (ACOR) News Today → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free ACOR Stock Alerts $0.66 -0.22 (-24.86%) (As of 04/11/2024) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAcorda Therapeutics (NASDAQ:ACOR) Now Covered by Analysts at StockNews.comamericanbankingnews.com - April 20 at 2:14 AMAcorda Therapeutics Announces Delisting from Nasdaqbusinesswire.com - April 15 at 5:03 PMAcorda Therapeutics, Inc. (NASDAQ:ACOR) Short Interest Updateamericanbankingnews.com - April 14 at 3:12 AMAcorda Therapeutics Inc.wsj.com - April 14 at 1:16 AMPearl River-based Acorda Therapeutics to close; 97 jobs impactedmsn.com - April 8 at 7:46 AMRiskiest Junk Bonds Shunned in Europe on Rising Risk of Defaultfinance.yahoo.com - April 6 at 6:32 PMAcorda Therapeutics Announces Nasdaq Delisting Notificationbusinesswire.com - April 3 at 5:30 PMAcorda Therapeutics Files for Chapter 11 Bankruptcybaystreet.ca - April 3 at 9:31 AMCrude Oil Surges Over 1%; US Factory Orders Increase In Februarymsn.com - April 2 at 1:28 PMWhy Acorda Therapeutics Stock Is Down Nearly 90%benzinga.com - April 2 at 1:28 PMmarketbeat.com - April 2 at 11:32 AMmarketbeat.com - April 2 at 11:05 AMmarketbeat.com - April 2 at 10:53 AMmarketbeat.com - April 2 at 10:27 AMmarketbeat.com - April 2 at 10:22 AMWhy Is Acorda Therapeutics (ACOR) Stock Down 72% Today?investorplace.com - April 2 at 8:57 AMNorth American Morning Briefing: Stocks Seen Weaker as Doubts Over Fed Cuts Mountmorningstar.com - April 2 at 8:28 AMMerz Therapeutics: Merz Enters Asset Purchase Agreement With a US-Based Biotech Companyfinanznachrichten.de - April 2 at 3:27 AMAcorda retires from PNP after 3 months of extended servicemsn.com - April 1 at 10:20 PMRetired PNP chief Acorda: I did my bestmsn.com - April 1 at 10:20 PMStocks to Watch: PVH, Canoo, Acorda Therapeuticsmarketwatch.com - April 1 at 10:20 PMAcorda Therapeutics shares sink nearly 40% after bankruptcy filingmsn.com - April 1 at 10:20 PMAcorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024finance.yahoo.com - April 1 at 5:15 PMAcorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024finance.yahoo.com - March 26 at 2:05 AMKlick Health Launches First AI Social Media Comment Moderator for Life Sciences Industryfinance.yahoo.com - March 11 at 12:42 PM3 Biotech Stocks to Watch in March for Successstocknews.com - February 28 at 1:01 PMAcorda Therapeutics Stock (NASDAQ:ACOR), Short Interest Reportbenzinga.com - February 23 at 8:16 AMAcorda Therapeutics Stock (NASDAQ:ACOR) Dividends: History, Yield and Datesbenzinga.com - February 22 at 10:23 AMAcorda: No policy vs. TikTok use in PNPmsn.com - February 20 at 10:36 AMAcorda: PNP can’t interfere with people’s initiative for Charter changemsn.com - February 6 at 3:58 PMTeodoro, Acorda nix Mindanao separation from Philippinesmsn.com - February 5 at 11:51 PMPNP chief Acorda tells ranks: Ignore ‘political noise’msn.com - January 31 at 12:46 PMDementia and Movement Disorder Treatment Market to Grow by USD 8.55 billion, Market Share, Trends, and Growth Analysis - Technaviofinance.yahoo.com - January 29 at 8:44 AMAcorda Therapeutics To Regain Worldwide Commercialization Rights To FAMPYRAmarkets.businessinsider.com - January 11 at 3:53 PM3 Biotech Stocks to Keep an Eye on in 2024stocknews.com - January 10 at 4:06 PMAcorda files raps vs person spreading false info in viral vlogmsn.com - January 8 at 5:51 PMAcorda slams vlogger in 'disinformation' drivemsn.com - January 8 at 12:51 PMAcorda files cybercrime raps vs person spreading false info in a vlogmsn.com - January 8 at 7:51 AMAcorda eyes Pinoy apps vs cybercrimesmsn.com - January 7 at 9:17 AMAcorda Therapeutics Inc ACORmorningstar.com - January 6 at 6:36 PMAshvattha Therapeutics Announces the Appointment of Mehdi Paborji as Senior Vice President of Technical Operationsfinance.yahoo.com - January 4 at 12:30 PMModerna (MRNA) and Acorda Therapeutics (ACOR): Buy, Hold, or Sell in 2024?stocknews.com - December 18 at 4:10 PMAcorda Therapeutics, Inc.'s (NASDAQ:ACOR) Shares Bounce 53% But Its Business Still Trails The Industryfinance.yahoo.com - December 18 at 7:22 AM3 Biotech Stocks Flashing Year-End 'Buy' Signals"stocknews.com - December 15 at 11:10 AM3 Safe Biotech Stocks to Buy This Weekstocknews.com - November 24 at 9:01 AMAcorda Therapeutics, Inc. (NASDAQ:ACOR) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 14 at 12:52 PMAcorda Therapeutics GAAP EPS of -$7.16, revenue of $27.72Mmsn.com - November 13 at 5:32 PMAcorda Therapeutics Reports Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 13 at 5:32 PMAcorda to PNP: Remain firm, united amid destabilization talkmsn.com - November 8 at 1:54 PMAcorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023finance.yahoo.com - November 6 at 6:33 PM Get Acorda Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter. Email Address This Apple-like Innovator is Revolutionizing Healthcare (Ad)AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world. Click here to learn more about the booming eHealth industry ACOR Media Mentions By Week ACOR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACOR News Sentiment▼0.000.44▲Average Medical News Sentiment ACOR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACOR Articles This Week▼11▲ACOR Articles Average Week Get Acorda Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SCNI News Today TCBP News Today SQZ News Today WINT News Today GMDA News Today ELOX News Today EVFM News Today EVLO News Today SXTC News Today AKAN News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACOR) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acorda Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
